Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 12,222 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Relapsed and Refractory Multiple Myeloma (RRMM)
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: sequential cord blood transplantation; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Up to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 32
States / cities: Muscle Shoals, Alabama • Anaheim, California • Bakersfield, California + 28 more

Conditions: Chronic Myelogenous Leukemia - Chronic Phase
Interventions: ABL001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: Anchorage, Alaska • Phoenix, Arizona • Long Beach, California + 21 more

Conditions: Multiple Sclerosis
Interventions: Linoleic Acid/Oleic Acid; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, Nirogacestat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 1 more

Conditions: Actinic Keratoses
Interventions: Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India; Drug
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more

Conditions: Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide; Radiation · Drug · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Alzheimer Disease
Interventions: NPT088, Placebo; Drug
Lead sponsor: Proclara Biosciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 23
States / cities: Costa Mesa, California • Fullerton, California • Long Beach, California + 20 more

Conditions: Dry Eye Disease
Interventions: licaminlimab, vehicle of OCS-02, Artificial tears; Drug · Other
Lead sponsor: Oculis; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Newport Beach, California • Colorado Springs, Colorado • Shelby, North Carolina + 2 more

Conditions: Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Chronic Conditions
Interventions: Patient Reported Outcome Measure (PROM), Comprehensive Medication Review (CMR), Communications between oncology and primary care pharmacists; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Excessive Daytime Sleepiness
Interventions: ORX142 Tablets, Placebo Tablets; Drug · Other
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Lincoln, Nebraska • Eatontown, New Jersey • New York, New York

Conditions: Graft Versus Host Disease
Interventions: Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: MIJ821, Placebo, Ketamine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Garden Grove, California • Oakland, California + 5 more

Conditions: Spinal; Nerve Root, Pain, Pelvic Pain, Regional Pain Syndrome, Chronic Pain Syndrome, Complex Regional Pain Syndromes
Interventions: dorsal root ganglion neuromodulation; Device
Lead sponsor: KM Clinical Research Group; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Murrieta, California

Conditions: Obesity, Type 2 Diabetes Mellitus (T2DM)
Interventions: K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatitis C Virus
Interventions: BMS-791325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
Interventions: Tirzepatide; Drug
Lead sponsor: Grace Kim; Other
Eligibility: 18 Years to 26 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Saint Paul, Minnesota • Nashville, Tennessee • Seattle, Washington

Conditions: Schizophrenia
Interventions: Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Upland, California

Conditions: Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions: 68Ga-Dotatate, 18F-DOPA; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months and older
Enrollment: 1,553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Daratumumab, Dexamethasone, Pomalidomide; Biological · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Wichita, Kansas • Rochester, Minnesota • Saint Louis Park, Minnesota + 2 more

Conditions: Multiple Myeloma
Interventions: Multi-modal Exercise Regimen, Dietary Guidelines; Other · Behavioral
Lead sponsor: Noha Mohamed Sharafeldin; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Injuries, Spinal Cord, CVA (Cerebrovascular Accident), Traumatic Brain Injury, MS (Multiple Sclerosis), Muscle Spasticity, Cerebral Palsy, Spastic
Interventions: Prometra II Programmable Pump - Flowonix Medical; Device
Lead sponsor: Culicchia Neurological Clinic; Other
Eligibility: 22 Years to 85 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Marrero, Louisiana

Conditions: Thrombocytopaenia
Interventions: SB497115, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 27
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Greenbrae, California + 23 more

Search by objective public record fields.

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Phase I Study of Sequential Cord Blood Transplants

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

Quality of Life and Pain Changes Due to DRG Stimulation for Chronic Pain

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Japanese Bridging Study Conducted in the United States

Tirzepatide in PWS, HO and GNSO

Staccato Loxapine in Agitation (Proof of Concept)

Studies of Elevated Parathyroid Activity

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Prehabilitation Feasibility Among Older Adults Undergoing Transplantation

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy